Promising Phase 3 Trial Results for Ulcerative Colitis Therapy Xeljanz Announced by Pfizer
News
Pfizer has just announced top-line results from OCTAVE Sustain, the third Phase 3 study investigating Xeljanz (tofacitinib citrate) in patients with moderate-to-severe active ulcerative colitis (UC). The OCTAVE Clinical Development ... Read more